Lundbeck

Part of LUNDBECKFONDEN (GLEIF)

CompanyDenmarkFounded 1915

Lundbeck develops 2 assets, the furthest approved (memantine in Alzheimer's disease). Mostly small molecule acting on GRIN2B, GRIN1 and GRIN2A; based in Denmark, founded in 1915.

2
Assets
Furthest: Approved; 14
Trials: 0
Signals

Pipeline

2

memantine
Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity
Approved, Small molecule, GRIN2B, GRIN1, Alzheimer's disease, dementia
Lu AF28996
D1/D2 receptor dopamine agonist for advanced Parkinson's disease
Phase 2, Small molecule, DRD2, DRD1, Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Trials26
Similar companies6

Updated 9 Oct 2026 · 73 sources